ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ARWR on Nasdaq
Shares outstanding
135,488,140
Price per share
$69.12
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
115,931,367
Total reported value
$7,697,364,248
% of total 13F portfolios
0.01%
Share change
+4,793,156
Value change
+$345,585,473
Number of holders
394
Price from insider filings
$69.12
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15% +8.6% $1,349,258,642 +$86,995,199 20,323,221 +6.9% BlackRock, Inc. 31 Dec 2025
VANGUARD GROUP INC 11% $245,296,138 15,525,072 The Vanguard Group 30 Jun 2025
Avoro Capital Advisors LLC 8.3% -13% $193,377,834 -$8,581,554 11,517,441 -4.2% Avoro Capital Advisors LLC 30 Jun 2025
STATE STREET CORP 4.6% -10% $106,970,030 -$10,547,360 6,371,056 -9% STATE STREET CORPORATION 30 Jun 2025

As of 31 Dec 2025, 394 institutional investors reported holding 115,931,367 shares of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR). This represents 86% of the company’s total 135,488,140 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 16% 21,318,582 +5.4% 0.02% $1,415,340,659
VANGUARD GROUP INC 11% 15,293,121 -4.6% 0.01% $1,015,310,304
Avoro Capital Advisors LLC 7.8% 10,625,000 -2.5% 7% $705,393,750
FMR LLC 4.8% 6,520,408 +13% 0.02% $432,889,919
STATE STREET CORP 4.7% 6,403,830 +0.1% 0.01% $425,150,274
GEODE CAPITAL MANAGEMENT, LLC 2.4% 3,264,963 +4.3% 0.01% $216,798,525
Slate Path Capital LP 1.9% 2,523,500 -49% 2.3% $167,535,165
BAKER BROS. ADVISORS LP 1.6% 2,175,645 +30% 0.85% $144,441,072
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.5% 2,087,953 +0.3% 0.08% $138,619,200
FRED ALGER MANAGEMENT, LLC 1.4% 1,832,997 +497% 0.48% $121,692,671
DEERFIELD MANAGEMENT COMPANY, L.P. 1.4% 1,832,946 +85% 1.6% $121,689,285
Driehaus Capital Management LLC 1.3% 1,769,340 -16% 0.8% $117,466,483
NORGES BANK 1.3% 1,704,464 0.01% $113,159,365
GOLDMAN SACHS GROUP INC 1.2% 1,677,522 -5.4% 0.02% $111,370,685
Siren, L.L.C. 1.1% 1,500,476 -44% 3% $99,616,602
MORGAN STANLEY 1.1% 1,476,004 -13% 0.01% $97,992,028
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1% 1,353,719 +0.58% 0.01% $89,873,404
NORTHERN TRUST CORP 0.99% 1,346,257 +2.6% 0.01% $89,378,003
Fisher Asset Management, LLC 0.97% 1,311,727 +24% 0.03% $87,085,554
JANUS HENDERSON GROUP PLC 0.95% 1,280,446 +32% 0.04% $84,997,093
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.93% 1,260,380 -28% 0.02% $83,676,628
Pictet Asset Management Holding SA 0.76% 1,028,736 +253% 0.07% $68,635,932
UBS Group AG 0.73% 987,287 +7.5% 0.01% $65,545,984
Vestal Point Capital, LP 0.66% 900,000 2.2% $59,751,000
Bank of New York Mellon Corp 0.66% 887,848 +9% 0.01% $58,944,211

Institutional Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 115,931,367 $7,697,364,248 +$345,585,473 $66.39 394
2025 Q3 110,909,853 $3,824,352,843 +$261,694,023 $34.49 300
2025 Q2 105,716,035 $1,671,181,802 +$44,748,514 $15.80 279
2025 Q1 103,362,113 $1,318,228,654 +$23,656,546 $12.74 258
2024 Q4 99,701,045 $1,874,384,692 +$32,738,534 $18.80 267
2024 Q3 97,715,477 $1,892,897,060 -$93,908,485 $19.37 267
2024 Q2 97,822,928 $2,542,052,894 +$57,202,679 $25.99 272
2024 Q1 96,658,787 $2,763,026,175 +$544,741,705 $28.60 267
2023 Q4 77,504,804 $2,371,960,338 +$86,943,186 $30.60 265
2023 Q3 74,643,254 $2,005,663,054 +$41,168,266 $26.87 253
2023 Q2 71,799,685 $2,559,646,627 -$10,508,327 $35.66 267
2023 Q1 72,976,301 $1,851,849,623 -$23,671,296 $25.40 250
2022 Q4 73,474,031 $2,977,955,799 +$97,292,640 $40.56 276
2022 Q3 71,284,086 $2,353,949,365 -$40,859,478 $33.05 264
2022 Q2 72,095,607 $2,538,257,759 +$100,531,936 $35.21 263
2022 Q1 69,254,530 $3,184,523,615 +$35,685,819 $45.99 294
2021 Q4 67,961,552 $4,505,834,422 +$55,872,415 $66.30 297
2021 Q3 66,549,683 $4,154,048,742 -$66,618,101 $62.43 282
2021 Q2 66,896,948 $5,539,659,575 -$140,144,186 $82.82 304
2021 Q1 68,464,454 $4,541,675,803 -$29,602,424 $66.31 281
2020 Q4 69,478,160 $5,331,874,119 +$80,806,659 $76.73 302
2020 Q3 68,146,322 $2,935,188,814 -$17,523,513 $43.06 252
2020 Q2 68,613,840 $2,962,938,209 +$129,556,464 $43.19 238
2020 Q1 65,790,124 $1,891,626,404 -$65,617,767 $28.77 228
2019 Q4 64,818,441 $4,111,036,094 -$251,364,075 $63.43 284
2019 Q3 65,607,783 $1,847,640,120 -$64,133,875 $28.18 215
2019 Q2 68,226,591 $1,809,138,980 +$469,493,968 $26.50 207
2019 Q1 58,944,394 $1,081,619,759 +$8,000,225 $18.35 172
2018 Q4 58,642,004 $728,108,442 +$2,744,915 $12.42 156
2018 Q3 55,874,420 $1,071,112,217 +$87,737,206 $19.17 131
2018 Q2 51,724,461 $703,394,391 +$174,211,743 $13.60 114
2018 Q1 40,751,284 $293,798,301 +$131,632,594 $7.21 88
2017 Q4 23,358,744 $85,959,545 +$30,381,058 $3.68 74
2017 Q3 15,003,494 $64,925,247 +$4,080,629 $4.33 54
2017 Q2 15,405,069 $24,955,147 -$15,547,121 $1.62 53
2017 Q1 24,329,456 $45,009,540 +$7,661,442 $1.85 78
2016 Q4 25,470,006 $39,473,542 -$54,918,365 $1.55 77
2016 Q3 30,122,030 $221,392,091 +$70,394,875 $7.35 94
2016 Q2 20,597,873 $109,582,112 +$97,619,255 $5.32 84
2016 Q1 2,128,149 $10,255,000 +$10,255,000 $4.82 6
2015 Q4 500 $4,000 $8.00 1
2015 Q3 500 $3,000 $6.00 1
2015 Q2 500 $4,000 $8.00 1
2015 Q1 500 $4,000 $8.00 1
2014 Q4 500 $4,000 $8.00 1